CD86 and leukemia: Treatment of the mice with leukemia using recombinant IL-12p70 (rIL-12) restored the numbers of these cells and enhanced the activation state of both conventional and plasmacytoid DCs, which expressed higher surface levels of T-cell costimulatory molecules (CD80 and CD86) and MHC class II molecules which present antigens to CD4+ T-cells (Fig. 3A).